Puma Biotechnology, Inc.
NASDAQ:PBYI · NASDAQ Global Select
+$0.16 today
Vol 0.33M · Avg 0.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.9%
avg 67.0%
ROIC
20.4%
avg -52.1%
ROA
14.4%
avg -41.9%
Analysis
ROE is currently the strongest return metric at 23.9% versus its period average of 67.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer & Secretary | $1.98M | — | 56 | $7.31M | 14.35% |
Maximo F. Nougues | Chief Financial Officer & Principal Accounting Officer | $904,486.00 | — | 57 | $240,023.00 | 0.47% |
Douglas Hunt FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer | $797,757.00 | — | 61 | $205,301.00 | 0.40% |
Pamela Wilson | Senior Vice President of Clinical Operations | — | — | — | $59,750.00 | 0.12% |
Roger L. Storms | Senior Vice President of Sales | — | — | — | — | — |
Gordon G. Esplin | Chief Accounting Officer | — | — | 58 | — | — |
Kenneth Wiehe | Senior Vice President of Supply Chain & Manufacturing | — | — | — | — | — |
Heather Blaber | Senior Vice President of Marketing | — | — | — | — | — |
Petra Rietschel | Senior Vice President of Clinical Development | — | — | — | — | — |
Mariann Ohanesian | Senior Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
19
$1.31M
Net Sentiment
$1.31M
Net selling
Most Active
HUNT DOUGLAS M
4 transactions
1–10 of 19
Analysis
Insiders reported 0 buys worth $0.00 and 19 sells worth $1.31M over the last 12 months. That adds up to net selling of $1.31M. HUNT DOUGLAS M was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$486.52M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$343.72M
Abeona Therapeutics Inc.
NASDAQ:ABEO
$325.16M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$265.73M
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
$226.63M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.26M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$216.99M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$211.47M
Humacyte, Inc.
NASDAQ:HUMA
$154.04M
Who manages PBYI?
Puma Biotechnology, Inc. (PBYI) lists 10 active executives. The top listed executive is Maximo F. Nougues, Chief Financial Officer & Principal Accounting Officer.
Are PBYI insiders buying or selling?
Recent insider activity shows net buying of $13.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.